EMA Lapsed: Lifmior (etanercept) — Pfizer Europe MA EEIG

View source ↗

Summary

The European Medicines Agency indicates Lifmior (etanercept) has lapsed; the product is no longer active in the market for its indicated conditions including ar…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ankylosing Spondylitis
• Arthritis
• Psoriasis
• Psoriatic Arthritis

Drugs mentioned

• Lifmior (etanercept)

Snippet

Status: Lapsed. Therapeutic area: Arthritis, Psoriatic;Spondylitis, Ankylosing;Psoriasis. MAH: Pfizer Europe MA EEIG. Decision date: 05/04/2019